AbbVie Settles Last Humira Suit, Protects Monopoly Until 2023

Drug Industry Daily
A A
AbbVie has settled its lawsuit with Boehringer Ingelheim, the last domino to fall in an all-out patent war that will protect AbbVie’s mega-blockbuster Humira until 2023.

To View This Article:

Login

Subscribe To Drug Industry Daily